NRx Pharmaceuticals has appointed Michael Abrams as the new Chief Financial Officer, succeeding Richard Narido, who will focus on acquisition opportunities for HOPE Therapeutics. Abrams ...
NRx Pharmaceuticals (NRXP) announced it has appointed Michael Abrams as its permanent CFO. Abrams succeeds Interim-CFO Richard Narido, who will continue to support the company’s financial ...
NRX Pharmaceuticals Inc (NASDAQ:NRXP) achieved a 74% reduction in net operating losses compared to the third quarter of 2023. The company is advancing its life-saving products, NRX-100 and NRX-101 ...
NRX Pharmaceuticals, Inc. is a clinical-stage small molecule pharmaceutical company. It engages in developing of novel therapeutics for the treatment of central nervous system disorders and life ...
"The rater training and monitoring methodology achieved by NRx's research team enabled the team to identify statistically significant improvements in recovery from suicidality and reduction in ...
MyChesCo on MSN2mon
NRx Pharmaceuticals Advances Towards FDA Approval with Key Stability Milestone for NRX-100RADNOR, PA — NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) has achieved a significant milestone in the development of its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback